<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral or transdermal opioids for osteoarthritis of the knee or hip - da Costa, BR - 2014 | Cochrane Library</title> <meta content="Oral or transdermal opioids for osteoarthritis of the knee or hip - da Costa, BR - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003115.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral or transdermal opioids for osteoarthritis of the knee or hip - da Costa, BR - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003115.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003115.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Oral or transdermal opioids for osteoarthritis of the knee or hip" name="citation_title"/> <meta content="Bruno R da Costa" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="bdacosta@ispm.unibe.ch" name="citation_author_email"/> <meta content="Eveline Nüesch" name="citation_author"/> <meta content="London School of Hygiene and Tropical Medicine" name="citation_author_institution"/> <meta content="Rahel Kasteler" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Elaine Husni" name="citation_author"/> <meta content="Cleveland Clinic: Orthopedic and Rheumatologic Institute" name="citation_author_institution"/> <meta content="Vivian Welch" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Anne WS Rutjes" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Peter Jüni" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD003115.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003115.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003115.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003115.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Cutaneous; Administration, Oral; Analgesics, Opioid [*administration &amp; dosage, adverse effects]; Osteoarthritis, Hip [*drug therapy]; Osteoarthritis, Knee [*drug therapy]; Pain Measurement; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003115.pub4&amp;doi=10.1002/14651858.CD003115.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003115\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003115\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","ta","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003115.pub4",title:"Oral or transdermal opioids for osteoarthritis of the knee or hip",firstPublishedDate:"Sep 17, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003115.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003115.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003115.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003115.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003115.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003115.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003115.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003115.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003115.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003115.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5661 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003115.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0059"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-sec-0054"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/appendices#CD003115-sec-0064"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/table_n/CD003115StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/table_n/CD003115StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral or transdermal opioids for osteoarthritis of the knee or hip</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bruno R da Costa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0003">Eveline Nüesch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0004">Rahel Kasteler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0005">Elaine Husni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0006">Vivian Welch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0007">Anne WS Rutjes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information#CD003115-cr-0008">Peter Jüni</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information/en#CD003115-sec-0070">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003115.pub4">https://doi.org/10.1002/14651858.CD003115.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003115-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003115-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003115-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003115-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003115-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003115-abs-0001" lang="en"> <section id="CD003115-sec-0001"> <h3 class="title" id="CD003115-sec-0001">Background</h3> <p>Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in older people. Opioids may be a viable treatment option if people have severe pain or if other analgesics are contraindicated. However, the evidence about their effectiveness and safety is contradictory. This is an update of a Cochrane review first published in 2009. </p> </section> <section id="CD003115-sec-0002"> <h3 class="title" id="CD003115-sec-0002">Objectives</h3> <p>To determine the effects on pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis. </p> </section> <section id="CD003115-sec-0003"> <h3 class="title" id="CD003115-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL (up to 28 July 2008, with an update performed on 15 August 2012), checked conference proceedings, reference lists, and contacted authors. </p> </section> <section id="CD003115-sec-0004"> <h3 class="title" id="CD003115-sec-0004">Selection criteria</h3> <p>We included randomised or quasi‐randomised controlled trials that compared oral or transdermal opioids with placebo or no treatment in people with knee or hip osteoarthritis. We excluded studies of tramadol. We applied no language restrictions. </p> </section> <section id="CD003115-sec-0005"> <h3 class="title" id="CD003115-sec-0005">Data collection and analysis</h3> <p>We extracted data in duplicate. We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain and function, and risk ratios for safety outcomes. We combined trials using an inverse‐variance random‐effects meta‐analysis. </p> </section> <section id="CD003115-sec-0006"> <h3 class="title" id="CD003115-sec-0006">Main results</h3> <p>We identified 12 additional trials and included 22 trials with 8275 participants in this update. Oral oxycodone was studied in 10 trials, transdermal buprenorphine and oral tapentadol in four, oral codeine in three, oral morphine and oral oxymorphone in two, and transdermal fentanyl and oral hydromorphone in one trial each. All trials were described as double‐blind, but the risk of bias for other domains was unclear in several trials due to incomplete reporting. Opioids were more beneficial in pain reduction than control interventions (SMD ‐0.28, 95% CI ‐0.35 to ‐0.20), which corresponds to a difference in pain scores of 0.7 cm on a 10‐cm visual analogue scale (VAS) between opioids and placebo. This corresponds to a difference in improvement of 12% (95% CI 9% to 15%) between opioids (41% mean improvement from baseline) and placebo (29% mean improvement from baseline), which translates into a number needed to treat (NNTB) to cause one additional treatment response on pain of 10 (95% CI 8 to 14). Improvement of function was larger in opioid‐treated participants compared with control groups (SMD ‐0.26, 95% CI ‐0.35 to ‐0.17), which corresponds to a difference in function scores of 0.6 units between opioids and placebo on a standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 11% (95% CI 7% to 14%) between opioids (32% mean improvement from baseline) and placebo (21% mean improvement from baseline), which translates into an NNTB to cause one additional treatment response on function of 11 (95% CI 7 to 14). We did not find substantial differences in effects according to type of opioid, analgesic potency, route of administration, daily dose, methodological quality of trials, and type of funding. Trials with treatment durations of four weeks or less showed larger pain relief than trials with longer treatment duration (P value for interaction = 0.001) and there was evidence for funnel plot asymmetry (P value = 0.054 for pain and P value = 0.011 for function). Adverse events were more frequent in participants receiving opioids compared with control. The pooled risk ratio was 1.49 (95% CI 1.35 to 1.63) for any adverse event (9 trials; 22% of participants in opioid and 15% of participants in control treatment experienced side effects), 3.76 (95% CI 2.93 to 4.82) for drop‐outs due to adverse events (19 trials; 6.4% of participants in opioid and 1.7% of participants in control treatment dropped out due to adverse events), and 3.35 (95% CI 0.83 to 13.56) for serious adverse events (2 trials; 1.3% of participants in opioid and 0.4% of participants in control treatment experienced serious adverse events). Withdrawal symptoms occurred more often in opioid compared with control treatment (odds ratio (OR) 2.76, 95% CI 2.02 to 3.77; 3 trials; 2.4% of participants in opioid and 0.9% of participants control treatment experienced withdrawal symptoms). </p> </section> <section id="CD003115-sec-0007"> <h3 class="title" id="CD003115-sec-0007">Authors' conclusions</h3> <p>The small mean benefit of non‐tramadol opioids are contrasted by significant increases in the risk of adverse events. For the pain outcome in particular, observed effects were of questionable clinical relevance since the 95% CI did not include the minimal clinically important difference of 0.37 SMDs, which corresponds to 0.9 cm on a 10‐cm VAS. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003115-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003115-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003115-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003115-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003115-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003115-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD003115-abs-0006">தமிழ்</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003115-abs-0003" lang="en"> <h3>Opioids for osteoarthritis</h3> <p>This summary of a Cochrane review of 22 studies with 8275 participants (search update: 15 August 2012) presents what we know from research about the effect of opioids on osteoarthritis (OA). We searched scientific databases for clinical trials looking at pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis. </p> <p><b>The review shows that in people with osteoarthritis:</b> </p> <p>‐ Opioids have a small effect on pain or physical function.<br/> ‐ Opioids probably cause side effects. However, we do not have precise information about rare but serious side effects. </p> <p><b>What is osteoarthritis and what are opioids?</b> </p> <p>OA is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try to repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee. </p> <p>Opioids are generally conceived as powerful pain‐relieving substances that are used for the pain of cancer or osteoarthritis. Some examples of opioids are codeine‐containing Tylenol® (1, 2, 3, and 4), hydromorphone (Dilaudid), oxycodone (Percocet, Percodan), morphine, and others. They can be taken in a pill form, as an injection, or as a patch placed on the painful area.  </p> <p><b>Best estimate of what happens to people with osteoarthritis who take opioids</b> </p> <p><b>Pain</b> </p> <p>‐ People who took opioids rated improvement in their pain to be about 3 points on a scale of 0 (no pain) to 10 (extreme pain) after one month.<br/> ‐ People who took a placebo rated improvement in their pain to be about 2 points on a scale of 0 (no pain) to 10 (extreme pain) after one month. </p> <p>Another way of saying this is:<br/> ‐ 41 people out of 100 who used opioids responded to treatment (41%).<br/> ‐ 31 people out of 100 who used placebo responded to treatment (31%).<br/> ‐ 10 more people responded to treatment with opioids than with placebo (difference of 10%). (High‐quality evidence) </p> <p><b>Physical function</b> </p> <p>‐ People who took opioids rated improvement in their physical function to be about 2 points on a scale of 0 (no disability) to 10 (extreme disability) after one month.<br/> ‐ People who took a placebo rated improvement in their physical function to be about 1 point on a scale of 0 (no disability) to 10 (extreme disability) after one month. </p> <p>Another way of saying this is:</p> <p>‐ 34 people out of 100 who used opioids responded to treatment (34%).<br/> ‐ 26 people out of 100 who used placebo responded to treatment (26%).<br/> ‐ 8 more people responded to treatment with opioids than with placebo (difference of 8%). (High‐quality evidence) </p> <p><b>Side effects</b> </p> <p>‐ 22 people out of 100 who used opioids experienced side effects (22%).<br/> ‐ 15 people out of 100 who used a placebo experienced side effects (15%).<br/> ‐ 7 more people experienced side effects with opioids than with placebo (difference of 7%). (Moderate‐quality evidence) </p> <p><b>Drop‐outs because of side effects</b> </p> <p>‐ 64 people out of 1000 who used opioids dropped out because of side effects (6.4%).<br/> ‐ 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).<br/> ‐ 47 more people dropped out because of side effects with opioids than with placebo (difference of 4.7%). (High‐quality evidence) </p> <p><b>Side effects resulting in hospitalisation, persistent disability, or death</b> </p> <p>‐ 13 people out of 1000 who used opioids experienced side effects resulting in hospitalisation, persistent disability, or death (1.3%).<br/> ‐ 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or deaths (0.4%).<br/> ‐ 9 more people experienced side effects resulting in hospitalisation, persistent disability, or death with opioids than with placebo (difference of 0.9%). (Low‐quality evidence) </p> <p><b>Withdrawal symptoms</b> </p> <p>‐ 24 people out of 1000 who used opioids experienced withdrawal symptoms (2.4%).<br/> ‐ 9 people out of 1000 who used a placebo experienced withdrawal symptoms (0.9%).<br/> ‐ 15 more people experienced withdrawal symptoms with opioids than with placebo (difference of 1.5%). (Moderate‐quality evidence) </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003115-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003115-sec-0059"></div> <h3 class="title" id="CD003115-sec-0060">Implications for practice</h3> <section id="CD003115-sec-0060"> <p>Opioids decrease pain intensity and improve function but the benefits observed are small. Dose increases do not appear to result in further pain reduction, while prolongation of treatment duration resulted in even smaller pain reduction. Observed effects for pain were of questionable clinical relevance since the 95% confidence intervals did not include the minimal clinically important difference of 0.37 standardised mean differences (SMDs), which corresponds to 0.9 cm on a 10‐cm visual analogue scale (VAS) (<a href="./references#CD003115-bbs2-0106" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ2010;341(16):c4675. ">Wandel 2010</a>; <a href="./references#CD003115-bbs2-0097" title="RutjesAW , JüniP , daCostaBR , TrelleS , NüeschE , ReichenbachS . Viscosupplementation for osteoarthritis of the knee: a systematic review and meta‐analysis. Annals of Internal Medicine2012;157(3):180‐91. ">Rutjes 2012</a>). The occurrence of adverse events caused one in 20 participants to stop taking the preparations, which is likely to limit their usefulness in the long‐term treatment of osteoarthritis of the hip or knee. The higher risk of serious adverse events and the occurrence of addiction to opioid therapy might further limit their clinical use, although evidence is limited by the short duration of follow‐up of the studies assessing these outcomes. Nevertheless, use of opioids might be warranted in special situations, such as for short‐term treatment of later stage osteoarthritis awaiting surgery. However, clinicians should inform participants about the substantial risks and only small benefits of opioid treatment and therapeutic alternatives. </p> </section> <h3 class="title" id="CD003115-sec-0061">Implications for research</h3> <section id="CD003115-sec-0061"> <p>The effectiveness and safety of opioid and non‐opioid analgesics in participants with inadequate pain relief should be directly compared in appropriately powered randomised controlled trials accompanied by separate Cochrane reviews or reviews of reviews including network meta‐analyses, which integrate direct and indirect evidence in one single analysis while maintaining randomisation (<a href="./references#CD003115-bbs2-0061" title="CaldwellDM , AdesAE , HigginsJP . Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ2005;331(7521):897‐900. ">Caldwell 2005</a>). The evidence of the effectiveness and safety of opioid therapy is mainly from a few short‐term trials, despite the fact that the underlying condition is chronic and requires safe, long‐term treatments (<a href="./references#CD003115-bbs2-0084" title="KalsoE , EdwardsJE , MooreRA , McQuayHJ . Opioids in chronic non‐cancer pain: systematic review of efficacy and safety. Pain2004;112(3):372‐80. ">Kalso 2004</a>; <a href="./references#CD003115-bbs2-0074" title="FurlanAD , SandovalJA , Mailis‐GagnonA , TunksE . Opioids for chronic noncancer pain: a meta‐analysis of effectiveness and side effects. Canadian Medical Association Journal2006;1(11):1589‐94. ">Furlan 2006</a>). Further long‐term observational studies would increase our understanding of their long‐term effectiveness, safety, and the potential for addiction. In addition, future trials might be performed in participants with clear failures of previous analgesic therapies with non‐steroidal anti‐inflammatory drugs or opioids and might target special subgroups, such as separately study and report participants with knee or hip osteoarthritis to acknowledge the different mechanisms resulting in pain in these two phenotypes, or participants with and without pain sensitisation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003115-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003115-sec-0022"></div> <div class="table" id="CD003115-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis of the knee or hip </p> <p><b>Settings:</b> various orthopaedic or rheumatology clinics </p> <p><b>Intervention: o</b>ral or transdermal opioids </p> <p><b>Comparison: p</b>lacebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intensity</b> </p> <p>Various pain scales.</p> <p>(median follow‐up: 4 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 cm change</b> <br/> on 10‐cm VAS<sup>1</sup> </p> <p>29% improvement</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐2.5 cm change</b> <br/> (Δ ‐0.7 cm, ‐0.9 to ‐0.5)<sup>2</sup> </p> <p><b>41% improvement</b> <br/> (Δ 12%, 9% to 15%)<sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.28 (‐0.35 to ‐0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8275<br/> (22) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 10 (95% CI 8 to 14)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> </p> <p>Various validated function scales.</p> <p>(median follow‐up: 5 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.2 units</b> <br/> on WOMAC (range 0 to 10)<sup>1</sup> </p> <p>21% improvement</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 units on WOMAC</b> <br/> (Δ ‐0.6, ‐0.8 to ‐0.4)<sup>5</sup> </p> <p><b>32% improvement</b> <br/> (Δ 11%, 7% to 14%)<sup>6</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.26 (‐0.35 to ‐0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3553<br/> (12) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 12 (95% CI 10 to 18)<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>(median follow‐up: 8 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000 participant‐years<br/> (203 to 245) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.49 (1.35 to 1.63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4898<br/> (9) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> moderate<sup>9</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 14 (95% CI 11 to 19)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew because of adverse events</b> </p> <p>(median follow‐up: 6 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000 participant‐years<br/> (50 to 82) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.76 (2.93 to 4.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7712<br/> (19) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 21 (95% CI 15 to 30)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse event</b> </p> <p>(median follow‐up: 8 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000 participant‐years<br/> (3 to 54) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.35 (0.83 to 13.56)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681<br/> (3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++OO<br/> low<sup>10</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little evidence of harmful effect (NNTH not statistically significant)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> <p>(median follow‐up: 16 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 1000 participant‐years<sup>11</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 100<br/> participant‐years<br/> (18 to 33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.67 (2.02 to 3.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1151<br/> (3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+++O<br/> moderate<sup>12</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 65 (95% CI 42 to 110)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RR: risk ratio; SMD: standardised mean difference; WOMAC: Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>GRADE Working Group grades of evidence<br/> <b>High quality (++++):</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality (+++O):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality (++OO):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality (+OOO):</b> We are very uncertain about the estimate. </p> <p><sup>1</sup> Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, <a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>2</sup> SMDs were back‐transformed onto a 10‐cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72 |SD units in the control group.<br/> <sup>3</sup> Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10‐cm VAS (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>4</sup> Absolute response risks for pain in the control groups were assumed 31% (see methods section).<br/> <sup>5</sup> SMDs were back‐transformed onto a standardised WOMAC disability score ranging from 0 to 10 on the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group.<br/> <sup>6</sup> Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>7</sup> Absolute response risks for function in the control groups were assumed 26% (see methods section).<br/> <sup>8</sup> Median control risk across placebo groups in large osteoarthritis trials (see methods section, <a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>9</sup> Downgraded (1 level) because: 9 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias.<br/> <sup>10</sup> Downgraded (2 levels) because: 3 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias, the CI of the pooled estimate is wide and crossed no difference.<br/> <sup>11</sup> Median risk across control groups in included trials.<br/> <sup>12</sup> Downgraded (1 level) because 3 out of 22 studies reported this outcome, possible leading to selective outcome reporting bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003115-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003115-sec-0023"></div> <section id="CD003115-sec-0024"> <h3 class="title" id="CD003115-sec-0024">Description of the condition</h3> <p>Osteoarthritis is the most common form of joint disease and the leading cause of pain, functional limitations, and loss of independence in older adults (<a href="./references#CD003115-bbs2-0056" title="AltmanR , AschE , BlochD , BoleG , BorensteinD , BrandtK , et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis and Rheumatism1986;29:1039‐49. ">Altman 1986</a>). It is a progressive disease of synovial joints resulting from biomechanical and systemic effects, and is characterised by a breakdown of the joint cartilage accompanied by subchondral bone changes, deterioration of tendons and ligaments, and various degrees of inflammation of the synovium (<a href="./references#CD003115-bbs2-0081" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care and Research2012;64(4):465‐74. ">Hochberg 2012</a>). </p> </section> <section id="CD003115-sec-0025"> <h3 class="title" id="CD003115-sec-0025">Description of the intervention</h3> <p>Pharmacological therapy for osteoarthritis, as an alternative or in addition to other therapeutic options, consists mainly of analgesics and non‐steroidal anti‐inﬂammatory drugs (NSAIDs). However, paracetamol may be inadequate to treat more severe, long‐term pain in osteoarthritis and chronic NSAID use may cause serious gastrointestinal and cardiovascular adverse events. Opioids could be a viable alternative if people have severe pain with insufficient response to conventional treatment or if other analgesics are contraindicated (<a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a>). </p> </section> <section id="CD003115-sec-0026"> <h3 class="title" id="CD003115-sec-0026">How the intervention might work</h3> <p>Opioids are potent analgesics that work by targeting mainly spinal and supraspinal opioid receptors. In addition, cellular studies suggest that there are peripheral opioid receptors in inflamed osteoarthritic synovial tissue, which may mediate analgesic effects (<a href="./references#CD003115-bbs2-0101" title="SteinC , PflugerM , YassouridisA , HoelzlJ , LehrbergerK , WelteC , et al. No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. Journal of Clinical Investigation1996;98:793‐9. ">Stein 1996</a>). </p> </section> <section id="CD003115-sec-0027"> <h3 class="title" id="CD003115-sec-0027">Why it is important to do this review</h3> <p>The American College of Rheumatology guidelines on management of osteoarthritis, updated in 2012, suggest that opioids can be used in people with osteoarthritis after having failed medical therapy who were not willing or had contraindications for total joint replacement (<a href="./references#CD003115-bbs2-0081" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care and Research2012;64(4):465‐74. ">Hochberg 2012</a>). British guidelines propose opioids as an alternative if inadequate pain relief is achieved with topical NSAIDs or paracetamol (<a href="./references#CD003115-bbs2-0070" title="EcclesM , FreemantleN , MasonJ . North of England Evidence Based Guidelines Development Project: summary guideline for non‐steroidal anti‐inflammatory drugs versus basic analgesics in treating of pain of degenerative arthritis. BMJ1998;317:526‐30. ">Eccles 1998</a>; <a href="./references#CD003115-bbs2-0087" title="NICE clinical guideline 59. Osteoarthritis ‐ the care and management of osteoarthritis in adults. www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf (accessed 16 August 2014). ">NICE 2008</a>). However, the use of strong opioids for the treatment of non‐cancer pain remains controversial. Concerns have been expressed about long‐term use of opioids for chronic non‐cancer pain mainly due to the risks of addiction (<a href="./references#CD003115-bbs2-0105" title="VonKorffM , DeyoRA . Potent opioids for chronic musculoskeletal pain: flying blind?. Pain2004;109(3):207‐9. ">Von Korff 2004</a>; <a href="./references#CD003115-bbs2-0107" title="ZhangW , MoskowitzRW , NukiG , AbramsonS , AltmanRD , ArdenN , et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence‐based, expert consensus guidelines. Osteoarthritis and Cartilage2008;16(2):137‐62. ">Zhang 2008</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003115-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003115-sec-0028"></div> <p>To determine the effects on pain, function, safety, and addiction of oral or transdermal opioids compared with placebo or no intervention in people with knee or hip osteoarthritis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003115-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003115-sec-0029"></div> <section id="CD003115-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003115-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised controlled trials with a control group receiving placebo or no intervention. </p> </section> <section id="CD003115-sec-0032"> <h4 class="title">Types of participants</h4> <p>At least 75% of participants with clinically or radiologically confirmed osteoarthritis of the knee or hip. We did not consider trials exclusively including people with inflammatory arthritis, such as rheumatoid arthritis. </p> </section> <section id="CD003115-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Any type of opioid except tramadol, which is covered in a separate Cochrane Review (<a href="./references#CD003115-bbs2-0062" title="CepedaMS , CamargoF , ZeaC , ValenciaL . Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005522.pub2] ">Cepeda 2006</a>). </p> </section> <section id="CD003115-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD003115-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>The main outcomes were pain and function, as currently recommended for osteoarthritis trials (<a href="./references#CD003115-bbs2-0057" title="AltmanR , BrandtK , HochbergM , MoskowitzR , BellamyN , BlochDA , et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis and Cartilage1996;4(4):217‐43. ">Altman 1996</a>; <a href="./references#CD003115-bbs2-0090" title="PhamT , van derHeijdeD , AltmanRD , AndersonJJ , BellamyN , HochbergM , et al. OMERACT‐OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis and Cartilage2004;12(5):389‐99. ">Pham 2004</a>). If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain‐related outcomes (<a href="./references#CD003115-bbs2-0083" title="JüniP , ReichenbachS , DieppeP . Osteoarthritis: rational approach to treating the individual. Best Practice &amp; Research. Clinical Rheumatology2006;20(4):721‐40. ">Jüni 2006</a>; <a href="./references#CD003115-bbs2-0091" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurgiE , BurgiU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146(8):580‐90. ">Reichenbach 2007</a>), and extracted data on the pain scale that was highest on this list: </p> <p> <ol id="CD003115-list-0001"> <li> <p>global pain;</p> </li> <li> <p>pain on walking;</p> </li> <li> <p>Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis index pain subscore; </p> </li> <li> <p>composite pain scores other than WOMAC;</p> </li> <li> <p>pain on activities other than walking;</p> </li> <li> <p>rest pain or pain during the night;</p> </li> <li> <p>WOMAC global algofunctional score;</p> </li> <li> <p>Lequesne osteoarthritis index global score;</p> </li> <li> <p>other algofunctional scale;</p> </li> <li> <p>participant's global assessment;</p> </li> <li> <p>physician's global assessment.</p> </li> </ol> </p> <p>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy: </p> <p> <ol id="CD003115-list-0002"> <li> <p>global disability score;</p> </li> <li> <p>walking disability;</p> </li> <li> <p>WOMAC disability subscore;</p> </li> <li> <p>composite disability scores other than WOMAC;</p> </li> <li> <p>disability other than walking;</p> </li> <li> <p>WOMAC global scale;</p> </li> <li> <p>Lequesne osteoarthritis index global score;</p> </li> <li> <p>other algofunctional scale;</p> </li> <li> <p>participant's global assessment;</p> </li> <li> <p>physician's global assessment.</p> </li> </ol> </p> <p>If pain or function outcomes were reported at several time points, we extracted the measure at the end of the treatment period. </p> </section> <section id="CD003115-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes were the number of participants who experienced any adverse event, withdrew because of adverse events, experienced any serious adverse events, and experienced symptoms of opioid dependence such as craving or physical withdrawal symptoms. We defined serious adverse events as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life‐threatening events, or death. </p> </section> </section> </section> <section id="CD003115-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003115-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the electronic databases the Cochrane Central Register of Controlled Trials (CENTRAL) (<a href="http://mrw.interscience.wiley.com/cochrane/" target="_blank">mrw.interscience.wiley.com/cochrane/</a>), MEDLINE and EMBASE through the Ovid platform (<a href="http://www.ovid.com" target="_blank">www.ovid.com</a>), and CINAHL through EBSCOhost (all from implementation to July 28 2008) using truncated variations of preparation names including brand names combined with truncated variations of terms related to osteoarthritis, all as text words. We applied a validated methodological filter for controlled clinical trials (<a href="./references#CD003115-bbs2-0069" title="DickersinK , SchererR , LefebvreC . Identifying relevant studies for systematic reviews. BMJ1994;309(6964):1286‐91. ">Dickersin 1994</a>). The specific search algorithms are displayed in <a href="./appendices#CD003115-sec-0065">Appendix 1</a> and <a href="./appendices#CD003115-sec-0066">Appendix 2</a>. We updated the search using CENTRAL, MEDLINE, and EMBASE up to 15 August 2012. </p> </section> <section id="CD003115-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We manually searched conference proceedings, used Science Citation Index to retrieve reports citing relevant articles, contacted content experts and trialists, and screened reference lists of all obtained articles. Finally, we searched several clinical trial registries (<a href="http://www.clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov</a>, <a href="http://www.controlled-trials.com" target="_blank">metaRegister of Controlled Trials</a>, <a href="http://www.anzctr.org.au" target="_blank">Australian New Zealand Clinical Trials Registry</a>, <a href="http://www.umin.ac.jp/ctr" target="_blank">UMIN Clinical Trials Registry</a>) to identify ongoing trials. We performed the last update of the search on 20 September 2012. We did not search OARSI conference proceedings for the update, as we no longer had access to this database. </p> </section> </section> <section id="CD003115-sec-0040"> <h3 class="title" id="CD003115-sec-0040">Data collection and analysis</h3> <p>We used a generic protocol with instructions for data extraction, quality assessment, and statistical analyses, which was approved by the editorial board of the Cochrane Musculoskeletal Group. We applied the same protocol in our previous reviews (<a href="./references#CD003115-bbs2-0094" title="RutjesAW , NüeschE , SterchiR , KalichmanL , HendriksE , OsiriM , et al. Transcutaneous electrostimulation for osteoarthritis of the knee. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002823.pub2] ">Rutjes 2009a</a>; <a href="./references#CD003115-bbs2-0095" title="RutjesAW , NueschE , ReichenbachS , JuniP . S‐Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007321.pub2] ">Rutjes 2009b</a>; <a href="./references#CD003115-bbs2-0092" title="ReichenbachS , RutjesAW , NüeschE , TrelleS , JüniP . Joint lavage for osteoarthritis of the knee. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD007320.pub2] ">Reichenbach 2010</a>; <a href="./references#CD003115-bbs2-0096" title="RutjesAW , NueschE , SterchiR , JuniP . Therapeutic ultrasound for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003132.pub2] ">Rutjes 2010</a>; <a href="./references#CD003115-bbs2-0067" title="daCostaBR , NüeschE , ReichenbachS , JüniP , RutjesAWS . Doxycycline for osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD007323.pub3] ">da Costa 2012b</a>). </p> <section id="CD003115-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently evaluated all titles and abstracts for eligibility (originally EN and AR, BdC and RK for the update) (see <a href="#CD003115-fig-0001">Figure 1</a>). We resolved disagreements by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all. </p> <div class="figure" id="CD003115-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow chart." data-id="CD003115-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow chart.</p> </div> </div> </div> </section> <section id="CD003115-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (originally EN and AR, BdC and RK for the update) extracted trial information independently using a standardised, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion. We extracted both the generic and trade name of the experimental intervention, the type of control used, dosage, frequency, route of administration, duration of treatment, participant characteristics (gender, mean age and duration of symptoms, types of joints affected), types of measures used and pain‐ and function‐related outcomes, trial design, trial size, duration of follow‐up, type and source of financial support, and publication status. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross‐over trials, we extracted data from the first period only. Whenever possible, we used results from an intention‐to‐treat analysis. If effect sizes could not be calculated, we contacted the authors for additional data. </p> </section> <section id="CD003115-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (originally EN and AR, BdC and RK for the update) independently assessed randomisation, blinding, and adequacy of analyses (<a href="./references#CD003115-bbs2-0082" title="JüniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>). We resolved disagreements by consensus. We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. We considered generation of sequences to be adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random‐number tables, computer‐generated random numbers, minimisation, coin tossing, shuffling cards, and drawing lots. We considered trials using an unpredictable allocation sequence to be randomised; we considered trials using potentially predictable allocation mechanisms, such as alternation or the allocation of participants according to date of birth, to be quasi‐randomised. We considered concealment of allocation to be adequate if participants and investigators responsible for participant selection were unable to suspect before allocation which treatment was next. Methods considered adequate include central randomisation; pharmacy‐controlled randomisation using identical pre‐numbered containers; and sequentially numbered, sealed, opaque envelopes. We considered blinding of participants to be adequate if experimental and control preparations were explicitly described as indistinguishable or if a double‐dummy technique was used. We considered analyses to be adequate if all randomised participants were included in the analysis according to the intention‐to‐treat principle. We further assessed the reporting of primary outcomes, sample size calculations, and funding source. Finally, we used GRADE to describe the quality of the overall body of evidence (<a href="./references#CD003115-bbs2-0077" title="GuyattG , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD003115-bbs2-0080" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), defined as the extent of confidence into the estimates of treatment benefits and harms. </p> </section> <section id="CD003115-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised continuous outcomes using standardised mean differences (SMD) with 95% confidence intervals (CI), with the differences in mean values at the end of treatment across treatment groups divided by the pooled standard deviation (SD). If differences in mean values at the end of the treatment were unavailable, we used differences in mean changes. If some of the required data were unavailable, we used approximations, as previously described (<a href="./references#CD003115-bbs2-0091" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurgiE , BurgiU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146(8):580‐90. ">Reichenbach 2007</a>). An SMD of ‐0.20 SD units can be considered a small difference between the experimental and control groups, an SMD of ‐0.50 a moderate difference, and ‐0.80 a large difference (<a href="./references#CD003115-bbs2-0065" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988. ">Cohen 1988</a>; <a href="./references#CD003115-bbs2-0083" title="JüniP , ReichenbachS , DieppeP . Osteoarthritis: rational approach to treating the individual. Best Practice &amp; Research. Clinical Rheumatology2006;20(4):721‐40. ">Jüni 2006</a>). SMDs can also be interpreted in terms of the per cent of overlap of the experimental group's scores with scores of the control group. An SMD of ‐0.20 indicates an overlap in the distribution of pain or function scores in about 85% of cases, an SMD of ‐0.50 in about 67%, and an SMD of ‐0.80 in about 53% of cases (<a href="./references#CD003115-bbs2-0065" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988. ">Cohen 1988</a>; <a href="./references#CD003115-bbs2-0083" title="JüniP , ReichenbachS , DieppeP . Osteoarthritis: rational approach to treating the individual. Best Practice &amp; Research. Clinical Rheumatology2006;20(4):721‐40. ">Jüni 2006</a>). On the basis of a median pooled SD of 2.5 cm, found in large‐scale osteoarthritis trials that assessed pain using a 10‐cm visual analogue scale (VAS) (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>), SMDs of ‐0.20 correspond to approximate differences in pain scores between experimental and control groups of 0.5 on a 10‐cm VAS, ‐0.50 of 1.25 on a 10‐cm VAS, and ‐0.80 of 2 on a 10‐cm VAS. We back transformed SMDs for function to a standardised WOMAC disability score (<a href="./references#CD003115-bbs2-0059" title="BellamyN . Outcome measurement in osteoarthritis clinical trials. Journal of Rheumatology Supplement1995;43:49‐51. ">Bellamy 1995</a>), ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large‐scale osteoarthritis trials (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>). We expressed binary outcomes as risk ratios (RR) with 95% CI. </p> </section> <section id="CD003115-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We used a standard inverse‐variance random‐effects meta‐analysis to combine the trials (<a href="./references#CD003115-bbs2-0068" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We quantified heterogeneity between trials using the I<sup>2</sup> statistic (<a href="./references#CD003115-bbs2-0079" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance. I<sup>2</sup> values of 25% may be interpreted as low, 50% as moderate, and 75% as high between‐trial heterogeneity, although its interpretation depends on the size and number of trials included (<a href="./references#CD003115-bbs2-0098" title="RückerG , SchwarzerG , CarpenterJR , SchumacherM . Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Medical Research Methodology2008;8(1):79. ">Rücker 2008</a>). The association between trial size and treatment effects was investigated in funnel plots, plotting effect sizes on the vertical axis against their standard errors on the horizontal axis (<a href="./references#CD003115-bbs2-0103" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). We assessed asymmetry by the asymmetry coefficient, the difference in effect size per unit increase in standard error (<a href="./references#CD003115-bbs2-0102" title="SterneJA , EggerM . Funnel plots for detecting bias in meta‐analysis: guidelines on choice of axis. Journal of Clinical Epidemiology2001;54(10):1046‐55. ">Sterne 2001</a>), which is mainly a surrogate for sample size, and used univariable, meta‐regression analysis to predict treatment effects in trials as large as the largest trials included in the meta‐analysis using the standard error as the explanatory variable (<a href="./references#CD003115-bbs2-0100" title="ShangA , Huwiler‐MuntenerK , NarteyL , JuniP , DorigS , SterneJA , et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo‐controlled trials of homoeopathy and allopathy. Lancet2005;366(9487):726‐32. ">Shang 2005</a>). We then performed analyses of the primary outcomes, pain and function, stratified by the following trial characteristics: type of opioid, analgesic potency (strong versus weak), route of administration (oral versus transdermal), type of control (placebo versus no intervention), concealment of allocation (adequate versus inadequate or unclear), blinding of participants (adequate versus inadequate or unclear), analysis in accordance with the intention‐to‐treat principle (yes versus no or unclear), trial size, funding (funding by pharmaceutical industry or unclear versus no funding by pharmaceutical industry), duration of treatment, and type of osteoarthritis (hip only versus knee only versus mixed). We classified buprenorphine, fentanyl, morphine, oxycodone, oxymorphone, and tapentadol as strong opioids, and codeine and dextropropoxyphene as weak opioids. We used a cut‐off of 200 allocated participants to distinguish between small‐scale and large‐scale trials. A sample size of 2 x 100 participants will yield more than 80% power to detect a small‐to‐moderate SMD of ‐0.40 at a two‐sided P value of 0.05, which corresponds to a difference of 1 cm on a 10‐cm VAS between the experimental and control intervention (<a href="./references#CD003115-bbs2-0089" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. ">Nüesch 2010</a>). We used a cut‐off of one month to distinguish between short‐term and long‐term trials. We used univariable, random‐effects meta‐regression models to determine whether treatment effects were affected by these factors (<a href="./references#CD003115-bbs2-0104" title="ThompsonSG , SharpSJ . Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine1999;18(20):2693‐708. ">Thompson 1999</a>). In addition, we included the following two continuous variables at trial level in univariable meta‐regression: daily morphine equivalence dosage and treatment duration. We calculated morphine equivalence doses as previously described: oral morphine 10 mg was considered equivalent to oral codeine 65 mg, oral hydromorphone 2 mg, oral oxycodone 7.5 mg, and oral oxymorphone 10 mg and oral tapentadol 25 mg (<a href="./references#CD003115-bbs2-0085" title="LoeserJD , ButlerSH , ChapmanCR , TurkDC . Bonica's Management of Pain. 3rd Edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001. ">Loeser 2001</a>; <a href="./references#CD003115-bbs2-0099" title="SchugSA , GandhamN . Opioids: clinical use. In: McMahonS , KlotzenburgM editor(s). Wall and Melzack's Textbook of Pain. 5th Edition. Oxford: Elsevier Limited, 2006:443‐57. ">Schug 2006</a>). Patches of fentanyl 25 μg/hour was considered equivalent to oral morphine 90 mg per day and patches of buprenorphine 5, 10, and 20 μg/hour equivalent to 10, 15, and 30 mg oral morphine per day (<a href="./references#CD003115-bbs2-0060" title="British Pain Society. Opioids for persistent pain: good practice, 2010. www.britishpainsociety.org/book_opioid_main.pdf (accessed 16 August 2014). ">British Pain Society 2010</a>). </p> <p>We converted SMDs of pain intensity and function to odds ratios (OR) (<a href="./references#CD003115-bbs2-0063" title="ChinnS . A simple method for converting an odds ratio to effect size for use in meta‐analysis. Statistics in Medicine2000;19(22):3127‐31. ">Chinn 2000</a>; <a href="./references#CD003115-bbs2-0066" title="daCostaBR , RutjesAWS , JohnstonBC , ReichenbachS , NüeschE , ToniaT , et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta‐epidemiological study. International Journal of Epidemiology2012;41(5):1445‐59. ">da Costa 2012a</a>) to derive numbers needed to treat to cause one additional treatment response on pain or function as compared with placebo (NNTB), and numbers needed to treat to cause one additional adverse outcome (NNTH). We defined treatment response as a 50% improvement in scores (<a href="./references#CD003115-bbs2-0064" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). With a median standardised pain intensity at baseline of 2.4 SD units, observed in large osteoarthritis trials (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>), this corresponds to a mean decrease in scores of 1.2 SD units. Based on the median standardised decrease in pain scores of 0.72 SD units (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>), we calculated that a median of 31% of participants in the placebo group would achieve an improvement of pain scores of 50% or more. This percentage was used as the control group response rate to calculate NNTBs for treatment response on pain. Based on the median standardised WOMAC function score at baseline of 2.7 SD units and the median standardised decrease in function scores of 0.58 SD units (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>), 26% of participants in the placebo group would achieve a reduction in function of 50% or more. Again, this percentage was used as the control group response rate to calculate NNTBs for treatment response on function. We used the median risks of 150 participants with adverse events per 1000 participant‐years, four participants with serious adverse events per 1000 participant‐years, and 17 drop‐outs due to adverse events per 1000 participant‐years as observed in placebo groups in large osteoarthritis trials (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>), to calculate NNTHs for safety outcomes. All P values were two‐sided. We performed analyses using Review Manager 5 (<a href="./references#CD003115-bbs2-0093" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>), and STATA version 11.2 (StataCorp, College Station, Texas). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003115-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003115-sec-0046"></div> <section id="CD003115-sec-0047"> <h3 class="title">Description of studies</h3> <p>We identified 5099 potentially relevant references through our electronic searches (<a href="#CD003115-fig-0001">Figure 1</a>); we excluded 4984 references after screening titles and abstracts and retrieved 115 potentially relevant references for full‐text assessment. We included 22 randomised controlled trials in the review. Checking reference lists, trial registers, and handsearching of conference proceedings yielded five additional trials. </p> <p>Three trials evaluated weak opioids. All three compared codeine with placebo (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>; <a href="./references#CD003115-bbs2-0019" title="PelosoPM , BellamyN , BensenW , ThomsonGTD , HarsanyiZ , BabulN , et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology2000;27(3):764‐71. ">Peloso 2000</a>), one of these with paracetamol 3000 mg daily as analgesic co‐intervention administered in both the experimental and control groups (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>), and another with ibuprofen 1200 mg daily administered in both groups (<a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>). Strong opioids were compared with placebo in 19 trials. Hydromorphone was used in one trial (<a href="./references#CD003115-bbs2-0018" title="Janssen‐Cilag . Placebo‐controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee. clinicaltrials.gov/show/NCT00980798 (accessed 16 August 2014). ">NCT00980798</a>), morphine in two trials (<a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>), oxymorphone in two trials (<a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>), oxycodone in 10 trials (<a href="./references#CD003115-bbs2-0004" title="ChindaloreVL , CravenRA , YuKP , ButeraPG , BurnsLH , FriedmannN . Adding ultra low‐dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex. Journal of Pain2005;6(6):392‐9. ">Chindalore 2005</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0022" title="ZautraAJ , SmithBW . Impact of controlled‐release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clinical Journal of Pain2005;21(6):471‐7. ">Zautra 2005</a>; <a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0005" title="EtropolskiM , KellyK , OkamotoA , RauschkolbC . Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy2011;28(5):401‐17. Johnson , Johnson . A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end‐stage joint disease. clinicaltrials.gov/show/NCT00784277 (accessed 16 August 2014). ">Etropolski 2011</a>; <a href="./references#CD003115-bbs2-0006" title="FidelholtzJ , TarkM , SpieringsE , WolframG , AnnisK , SmithMD , et al. A phase 3 placebo‐ and oxycodone‐controlled study of tanezumab in adults with osteoarthritis. Proceedings of the ACR/ARHP Scientific Meeting; 2011 Nov 9‐11; Chicago. Pfizer . Tanezumab in osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00985621 (accessed 16 August 2014). ">Fidelholtz 2011</a>; <a href="./references#CD003115-bbs2-0007" title="FriedmannN , KlutzaritzV , WebsterL . Efficacy and safety of an extended‐release oxycodone (Remoxy®) formulation in patients with moderate to severe osteoarthritic pain. Journal of Opioid Management2011;7(3):193‐202. ">Friedmann 2011</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>), and tapentadol in four trials (<a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0005" title="EtropolskiM , KellyK , OkamotoA , RauschkolbC . Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy2011;28(5):401‐17. Johnson , Johnson . A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end‐stage joint disease. clinicaltrials.gov/show/NCT00784277 (accessed 16 August 2014). ">Etropolski 2011</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>). Transdermal opioids were studied in five trials: buprenorphine in four trials (<a href="./references#CD003115-bbs2-0021" title="LandauCJ , ShannonM , KivitzAJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Arthritis and Rheumatism2008;58(Suppl 9):866. Purdue . Safety and efficacy of buprenorphine transdermal system in subjects with moderate to severe osteoarthritis of hip or knee. clinicaltrials.gov/show/NCT00313846 (accessed 16 August 2014). ShannonMJ , KivitzAJ , LandauCJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Archives of Physical Medicine and Rehabilitation2005;86:E32. ">Shannon 2005</a>; <a href="./references#CD003115-bbs2-0002" title="BreivikH , LjosaaTM , Stengaard‐PedersenK , PerssonJ , AroH , VillumsenJ , et al. A 6‐months, randomised, placebo‐controlled evaluation of efficacy and tolerability of a low‐dose 7‐day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain2010;1:122‐41. ">Breivik 2010</a>; <a href="./references#CD003115-bbs2-0015" title="MuneraC , DrehoblM , SesslerNE , LandauC . A randomized, placebo‐controlled, double‐blinded, parallel‐group, 5‐week study of buprenorphine transdermal system in adults with osteoarthritis. Journal of Opioid Management2010;6(3):193‐202. Purdue . Safety and efficacy of the buprenorphine transdermal delivery system in subjects with osteoarthritis pain. clinicaltrials.gov/show/NCT00314652 (accessed 16 August 2014). ">Munera 2010</a>; <a href="./references#CD003115-bbs2-0017" title="Purdue . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00531427 (accessed 16 August 2014). ">NCT00531427</a>), and fentanyl in one trial (<a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>). Opioids were administered at a median daily dose of 59‐mg morphine equivalents (range 13 to 160 mg). </p> <p>The median treatment duration was four weeks (range three days to six months). Trials randomised a median of 344 participants (range 27 to 10301 participants). Twenty trials (90%) were multicentre trials, 21 were parallel group, and one was a cross‐over trial (<a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>). Two trials exclusively included participants with hip osteoarthritis (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>), four trials included only participants with knee osteoarthritis (<a href="./references#CD003115-bbs2-0022" title="ZautraAJ , SmithBW . Impact of controlled‐release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clinical Journal of Pain2005;21(6):471‐7. ">Zautra 2005</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT0048681</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a><a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">1</a>; <a href="./references#CD003115-bbs2-0017" title="Purdue . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00531427 (accessed 16 August 2014). ">NCT00531427</a>), and 16 trials included a mixed population of both knee and hip osteoarthritis (<a href="./references#CD003115-bbs2-0019" title="PelosoPM , BellamyN , BensenW , ThomsonGTD , HarsanyiZ , BabulN , et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology2000;27(3):764‐71. ">Peloso 2000</a>; <a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0004" title="ChindaloreVL , CravenRA , YuKP , ButeraPG , BurnsLH , FriedmannN . Adding ultra low‐dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex. Journal of Pain2005;6(6):392‐9. ">Chindalore 2005</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0021" title="LandauCJ , ShannonM , KivitzAJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Arthritis and Rheumatism2008;58(Suppl 9):866. Purdue . Safety and efficacy of buprenorphine transdermal system in subjects with moderate to severe osteoarthritis of hip or knee. clinicaltrials.gov/show/NCT00313846 (accessed 16 August 2014). ShannonMJ , KivitzAJ , LandauCJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Archives of Physical Medicine and Rehabilitation2005;86:E32. ">Shannon 2005</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>; <a href="./references#CD003115-bbs2-0002" title="BreivikH , LjosaaTM , Stengaard‐PedersenK , PerssonJ , AroH , VillumsenJ , et al. A 6‐months, randomised, placebo‐controlled evaluation of efficacy and tolerability of a low‐dose 7‐day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain2010;1:122‐41. ">Breivik 2010</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>; <a href="./references#CD003115-bbs2-0015" title="MuneraC , DrehoblM , SesslerNE , LandauC . A randomized, placebo‐controlled, double‐blinded, parallel‐group, 5‐week study of buprenorphine transdermal system in adults with osteoarthritis. Journal of Opioid Management2010;6(3):193‐202. Purdue . Safety and efficacy of the buprenorphine transdermal delivery system in subjects with osteoarthritis pain. clinicaltrials.gov/show/NCT00314652 (accessed 16 August 2014). ">Munera 2010</a>; <a href="./references#CD003115-bbs2-0005" title="EtropolskiM , KellyK , OkamotoA , RauschkolbC . Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy2011;28(5):401‐17. Johnson , Johnson . A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end‐stage joint disease. clinicaltrials.gov/show/NCT00784277 (accessed 16 August 2014). ">Etropolski 2011</a>; <a href="./references#CD003115-bbs2-0006" title="FidelholtzJ , TarkM , SpieringsE , WolframG , AnnisK , SmithMD , et al. A phase 3 placebo‐ and oxycodone‐controlled study of tanezumab in adults with osteoarthritis. Proceedings of the ACR/ARHP Scientific Meeting; 2011 Nov 9‐11; Chicago. Pfizer . Tanezumab in osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00985621 (accessed 16 August 2014). ">Fidelholtz 2011</a>; <a href="./references#CD003115-bbs2-0007" title="FriedmannN , KlutzaritzV , WebsterL . Efficacy and safety of an extended‐release oxycodone (Remoxy®) formulation in patients with moderate to severe osteoarthritic pain. Journal of Opioid Management2011;7(3):193‐202. ">Friedmann 2011</a>; <a href="./references#CD003115-bbs2-0018" title="Janssen‐Cilag . Placebo‐controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee. clinicaltrials.gov/show/NCT00980798 (accessed 16 August 2014). ">NCT00980798</a>). In 17 studies, only participants with insufficient analgesic response to paracetamol, NSAIDs, or previous opioid treatment were included (<a href="./references#CD003115-bbs2-0018" title="Janssen‐Cilag . Placebo‐controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee. clinicaltrials.gov/show/NCT00980798 (accessed 16 August 2014). ">NCT00980798</a>; <a href="./references#CD003115-bbs2-0017" title="Purdue . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00531427 (accessed 16 August 2014). ">NCT00531427</a>; <a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0004" title="ChindaloreVL , CravenRA , YuKP , ButeraPG , BurnsLH , FriedmannN . Adding ultra low‐dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of oxytrex. Journal of Pain2005;6(6):392‐9. ">Chindalore 2005</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0021" title="LandauCJ , ShannonM , KivitzAJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Arthritis and Rheumatism2008;58(Suppl 9):866. Purdue . Safety and efficacy of buprenorphine transdermal system in subjects with moderate to severe osteoarthritis of hip or knee. clinicaltrials.gov/show/NCT00313846 (accessed 16 August 2014). ShannonMJ , KivitzAJ , LandauCJ , SesslerNE , XiaY , RipaSR . Buprenorphine transdermal system in chronic pain due to osteoarthritis. Archives of Physical Medicine and Rehabilitation2005;86:E32. ">Shannon 2005</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0002" title="BreivikH , LjosaaTM , Stengaard‐PedersenK , PerssonJ , AroH , VillumsenJ , et al. A 6‐months, randomised, placebo‐controlled evaluation of efficacy and tolerability of a low‐dose 7‐day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain2010;1:122‐41. ">Breivik 2010</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>; <a href="./references#CD003115-bbs2-0015" title="MuneraC , DrehoblM , SesslerNE , LandauC . A randomized, placebo‐controlled, double‐blinded, parallel‐group, 5‐week study of buprenorphine transdermal system in adults with osteoarthritis. Journal of Opioid Management2010;6(3):193‐202. Purdue . Safety and efficacy of the buprenorphine transdermal delivery system in subjects with osteoarthritis pain. clinicaltrials.gov/show/NCT00314652 (accessed 16 August 2014). ">Munera 2010</a>; <a href="./references#CD003115-bbs2-0005" title="EtropolskiM , KellyK , OkamotoA , RauschkolbC . Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy2011;28(5):401‐17. Johnson , Johnson . A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end‐stage joint disease. clinicaltrials.gov/show/NCT00784277 (accessed 16 August 2014). ">Etropolski 2011</a>; <a href="./references#CD003115-bbs2-0007" title="FriedmannN , KlutzaritzV , WebsterL . Efficacy and safety of an extended‐release oxycodone (Remoxy®) formulation in patients with moderate to severe osteoarthritic pain. Journal of Opioid Management2011;7(3):193‐202. ">Friedmann 2011</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>). None of these trials provided detailed information about the dosage of the analgesic treatments before entering the trial. The three trials assessing codeine included participants with a need for analgesic treatment but without any requirement of previous insufficient treatment response (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>; <a href="./references#CD003115-bbs2-0019" title="PelosoPM , BellamyN , BensenW , ThomsonGTD , HarsanyiZ , BabulN , et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology2000;27(3):764‐71. ">Peloso 2000</a>); two trials did not provide information about eligibility criteria concerning the previous analgesic therapy (<a href="./references#CD003115-bbs2-0022" title="ZautraAJ , SmithBW . Impact of controlled‐release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clinical Journal of Pain2005;21(6):471‐7. ">Zautra 2005</a>; <a href="./references#CD003115-bbs2-0006" title="FidelholtzJ , TarkM , SpieringsE , WolframG , AnnisK , SmithMD , et al. A phase 3 placebo‐ and oxycodone‐controlled study of tanezumab in adults with osteoarthritis. Proceedings of the ACR/ARHP Scientific Meeting; 2011 Nov 9‐11; Chicago. Pfizer . Tanezumab in osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00985621 (accessed 16 August 2014). ">Fidelholtz 2011</a>). </p> <p>The <a href="./references#CD003115-sec-0077" title="">Characteristics of excluded studies</a> table displays the reasons why we did not consider trials in this systematic review. Typical reasons were more than 25% of participants with rheumatoid arthritis in the sample, the use of active control interventions, or the use of cross‐over designs without providing sufficient information on the first phase. </p> </section> <section id="CD003115-sec-0048"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD003115-fig-0002">Figure 2</a> summarises the methodological characteristics and sources of funding of included trials. Six trials (27%) reported both adequate sequence generation and adequate allocation concealment (<a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0002" title="BreivikH , LjosaaTM , Stengaard‐PedersenK , PerssonJ , AroH , VillumsenJ , et al. A 6‐months, randomised, placebo‐controlled evaluation of efficacy and tolerability of a low‐dose 7‐day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain2010;1:122‐41. ">Breivik 2010</a>; <a href="./references#CD003115-bbs2-0005" title="EtropolskiM , KellyK , OkamotoA , RauschkolbC . Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy2011;28(5):401‐17. Johnson , Johnson . A study to compare the frequency of constipation symptoms with tapentadol immediate release (IR) treatment versus oxycodone IR treatment in patients with end‐stage joint disease. clinicaltrials.gov/show/NCT00784277 (accessed 16 August 2014). ">Etropolski 2011</a>), two trials reported only adequate sequence generation (<a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>), and two trials reported adequate concealment but remained unclear about the generation of allocation sequence (<a href="./references#CD003115-bbs2-0022" title="ZautraAJ , SmithBW . Impact of controlled‐release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clinical Journal of Pain2005;21(6):471‐7. ">Zautra 2005</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>). In the remaining 12 trials, low quality of reporting hampered any judgement regarding sequence generation and concealment of allocation. All 22 trials were described as double blind. Eleven trials reported the use of indistinguishable interventions to blind participants whereas another four trials used double‐dummy techniques (<a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>; <a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>). Fourteen trials explicitly reported adequate blinding of physicians. Seventeen trials described their analysis to be according to the intention‐to‐treat principle, but only one trial was considered to have an intention‐to‐treat analysis of pain (<a href="./references#CD003115-bbs2-0017" title="Purdue . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00531427 (accessed 16 August 2014). ">NCT00531427</a>), and one trial of function outcomes at end of treatment (<a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>), according to our criteria. Exclusion of participants from the analysis of pain outcomes ranged from 0.6% to 52% in the experimental groups and from 0% to 33% in the control groups. For eight trials, no information was available on the proportion of excluded participants (<a href="./references#CD003115-bbs2-0018" title="Janssen‐Cilag . Placebo‐controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee. clinicaltrials.gov/show/NCT00980798 (accessed 16 August 2014). ">NCT00980798</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>; <a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0008" title="HartrickC , VanHoveI , StegmannJU , OhC , UpmalisD . Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end‐stage joint disease: a 10‐day, phase III, randomized, double‐blind, active‐ and placebo‐controlled study. Clinical Therapeutics2009;31(2):260‐71. Johnson , Johnson . A study to evaluate the effectiveness and safety of multiple doses of tapentadol (CG5503) in patients awaiting joint replacement surgery. clinicaltrials.gov/show/NCT00361582 (accessed 16 August 2014). ">Hartrick 2009</a>; <a href="./references#CD003115-bbs2-0006" title="FidelholtzJ , TarkM , SpieringsE , WolframG , AnnisK , SmithMD , et al. A phase 3 placebo‐ and oxycodone‐controlled study of tanezumab in adults with osteoarthritis. Proceedings of the ACR/ARHP Scientific Meeting; 2011 Nov 9‐11; Chicago. Pfizer . Tanezumab in osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00985621 (accessed 16 August 2014). ">Fidelholtz 2011</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>). For the analysis of function outcomes, exclusion of participants ranged from 1% to 73% in the experimental groups and from 0.6% to 53% in the control groups; in four trials, no information was available on the proportion of excluded patients (<a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>). </p> <div class="figure" id="CD003115-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (‐) a high risk of bias on a specific item." data-id="CD003115-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (‐) a high risk of bias on a specific item. </p> </div> </div> </div> <p>All trials (95%) except for one (<a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>) reported a primary outcome of which eight explicitly reported it to be pre‐specified in the protocol (<a href="./references#CD003115-bbs2-0019" title="PelosoPM , BellamyN , BensenW , ThomsonGTD , HarsanyiZ , BabulN , et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. Journal of Rheumatology2000;27(3):764‐71. ">Peloso 2000</a>; <a href="./references#CD003115-bbs2-0003" title="CaldwellJR , RapoportRJ , DavisJC , OffenbergHL , MarkerHW , RothSH , et al. Efficacy and safety of a once‐daily morphine formulation in chronic, moderate‐to‐severe osteoarthritis pain: results from a randomized, placebo‐controlled, double‐blind trial and an open‐label extension trial. Journal of Pain and Symptom Management2002;23(4):278‐91. ">Caldwell 2002</a>; <a href="./references#CD003115-bbs2-0013" title="MarkensonJA , CroftJ , ZhangPG , RichardsP . Treatment of persistent pain associated with osteoarthritis with controlled‐release oxycodone tablets in a randomized controlled clinical trial. Clinical Journal of Pain2005;21(6):524‐35. ">Markenson 2005</a>; <a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>; <a href="./references#CD003115-bbs2-0017" title="Purdue . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00531427 (accessed 16 August 2014). ">NCT00531427</a>), and 13 trials reported a sample size calculation for this primary outcome. Twenty trials received financial support from a commercial organisation, two were unclear about their source of funding (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>), whereas no trial was explicitly supported by a non‐profit organisation. For the effectiveness outcomes pain and function, the quality of the evidence (<a href="./references#CD003115-bbs2-0077" title="GuyattG , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>) was classified as high in view of the low risk of bias in the included trials and the low heterogeneity between trials (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). For adverse event and serious adverse event outcomes, the quality of the evidence (<a href="./references#CD003115-bbs2-0077" title="GuyattG , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>) was classified as moderate to low because of the small number of trials reporting the outcomes and the small number of serious adverse events, which resulted in imprecise estimates (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD003115-sec-0049"> <h3 class="title" id="CD003115-sec-0049">Effects of interventions</h3> <p>See: <a href="./full#CD003115-tbl-0001"><b>Summary of findings for the main comparison</b> Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</a> </p> <section id="CD003115-sec-0050"> <h4 class="title">Primary outcomes</h4> <section id="CD003115-sec-0051"> <h5 class="title">Knee or hip pain</h5> <p>Twenty‐two trials including 5180 participants in experimental groups and 3095 participants in control groups contributed to the analyses of knee or hip pain. <a href="#CD003115-fig-0003">Figure 3</a> presents results of the analysis, overall and stratified according to type of opioid. In the overall analysis, combined oral and transdermal opioids were more effective in pain reduction than control interventions (SMD ‐0.28, 95% CI ‐0.35 to ‐0.20), which corresponds to a difference in pain scores of 0.7 cm on a 10‐cm VAS between opioids and placebo. This corresponds to a difference in improvement of 12% (95% CI 9% to 15%) between opioids and placebo (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>), which translates into an NNTB to cause one additional treatment response on pain of 10 (95% CI 8 to 14) (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). An I<sup>2</sup> statistic of 58% indicated a moderate degree of between‐trial heterogeneity (P for heterogeneity &lt; 0.001). A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient ‐1.86, 95% CI ‐3.50 to ‐0.21) and the test for asymmetry indicated some evidence for asymmetry (P value = 0.054) (<a href="#CD003115-fig-0004">Figure 4</a>). Benefits were moderate for codeine (SMD ‐0.51, 95% CI ‐1.01 to ‐0.01; 3 trials); small to moderate for oxycodone (SMD ‐0.31, 95% CI ‐0.47 to ‐0.15; 10 trials), oxymorphone (SMD ‐0.39, 95% CI ‐0.58 to ‐0.21; 2 trials), and tapentadol (SMD ‐0.31, 95% CI ‐0.46 to ‐0.16, 4 trials); and small for morphine (SMD ‐0.25, 95% CI ‐0.42 to ‐0.09; 2 trials) and transdermal opioids such as buprenorphine (SMD ‐0.19, 95% CI ‐0.30 to ‐0.09, 4 trials) and fentanyl (SMD ‐0.22, 95% CI ‐0.42 to ‐0.03; 1 trial). No benefit was observed for hydromorphone (SMD 0.04, 95% CI ‐0.19 to 0.28, 1 trial). The CIs were wide and a test for interaction between benefit and type of opioid was non‐significant (P value = 0.66). <a href="#CD003115-tbl-0002">Table 1</a> presents the results of stratified analyses. We found little evidence for an association of SMDs with analgesic potency, route of administration, type of control intervention, use of analgesic co‐interventions, type of osteoarthritis, concealment of allocation, adequate blinding of participants, or intention‐to‐treat analysis. Effects were similar in studies including participants with only knee osteoarthritis (SMD ‐0.22, 95% CI ‐0.41 to ‐0.04, 4 trials), with only hip osteoarthritis (SMD ‐0.33, 95% CI ‐0.93 to 0.28, 2 trials), and with knee or hip osteoarthritis (SMD ‐0.29, 95% CI ‐0.38 to ‐0.20, 16 trials, P value for interaction = 0.77). We found larger benefits in trials with 200 or fewer randomised participants (difference in SMD ‐0.23, 95% CI ‐0.49 to 0.02, P for interaction = 0.08) and in trials with a short treatment duration of one month or less (difference in SMD ‐0.25, 95% CI ‐0.37 to ‐0.13, P value for interaction = 0.001). The effect of treatment duration on treatment benefits was similar, when we restricted the analyses to large trials only (P value for interaction 0.001). Thirty‐three comparisons from 22 trials contributed to the analysis of a linear association between equivalence dose and treatment benefit (<a href="#CD003115-fig-0005">Figure 5</a>). We found little evidence for a linear association between daily equivalence doses and pain reduction (P value = 0.49). </p> <div class="figure" id="CD003115-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no intervention) on knee or hip pain. Values on x‐axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled." data-id="CD003115-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no intervention) on knee or hip pain. Values on x‐axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled. </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot for effects on knee or hip pain.  Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs." data-id="CD003115-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for effects on knee or hip pain.<br/> Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs. </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> </div> <div class="table" id="CD003115-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stratified analyses: pain</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Variable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of</b> <br/> <b>studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>opioids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intensity</b> <br/> SMD (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> <br/> I<sup>2</sup> (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.35 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Analgesic potency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.51 (‐1.01 to ‐0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.35 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.41 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transdermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.29 to ‐0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.44 to ‐0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.35 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.42 to ‐0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.34 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 (‐0.30 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.37 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of control intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.36 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.93 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Number of participants randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.47 (‐0.71 to ‐0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.15 (‐0.22 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.40 (‐0.50 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Use of analgesic co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.46 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.36 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of osteoarthritis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hip only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.93 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.22 (‐0.41 to ‐0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee and hip</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.38 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>*P value for interaction. N/A: not available.</p> </div> </div> </section> <section id="CD003115-sec-0052"> <h5 class="title">Function</h5> <p>Twelve studies including 2124 participants in experimental groups and 1429 participants in control groups contributed to the analysis of function. Improvement of function was larger in opioid‐treated participants compared with control groups (SMD ‐0.26, 95% CI ‐0.35 to ‐0.17) (<a href="#CD003115-fig-0006">Figure 6</a>), which corresponds to a difference in function scores of 0.6 units between opioids and placebo on a standardised WOMAC disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 11% (95% CI 7% to 14%) between opioids and placebo (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>), which translates into an NNTB to cause one additional treatment response on function of 11 (95% CI 7 to 14) (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). An I<sup>2</sup> statistic of 32% indicated a low degree of between‐trial heterogeneity (P value for heterogeneity = 0.12). We found a moderate benefit for codeine (SMD ‐0.42, 95% CI ‐0.74 to ‐0.10; 2 trials) and oxymorphone (SMD ‐0.38, 95% CI ‐0.56 to ‐0.19, 2 trials) and small benefits for morphine (SMD ‐0.20, 95% CI ‐0.38 to ‐0.02, 2 trials), oxycodone (SMD ‐0.30, 95% CI ‐0.58 to ‐0.01, 4 trials), tapentadol (SMD ‐0.15, 95% CI ‐0.45 to 0.16, 2 trials), and for transdermal opioids such as buprenorphine (SMD ‐0.23, 95% CI ‐0.40 to ‐0.05, 2 trials) and fentanyl (SMD ‐0.28, 95% CI ‐0.48 to ‐0.09; 1 trial). As was the case for pain, CIs of estimates were wide and a test for interaction between benefit and type of opioid was non‐significant (P value = 0.87). Heterogeneity between trials was low with an I<sup>2</sup> statistic estimate of 32% (P value for heterogeneity = 0.12). The funnel plot (<a href="#CD003115-fig-0007">Figure 7</a>) appeared asymmetrical (asymmetry coefficient ‐3.33, 95% CI ‐5.76 to ‐0.89, P value for asymmetry = 0.011). <a href="#CD003115-tbl-0003">Table 2</a> presents the results of the stratified analyses. We found little evidence for an association of SMDs with analgesic potency, route of administration, type of control intervention, treatment duration, use of analgesic co‐interventions, type of osteoarthritis, allocation concealment, and intention‐to‐treat analysis. Effects were similar in studies including participants with only knee osteoarthritis (SMD ‐0.16, 95% CI ‐0.43 to 0.11, 2 trials), only hip OA (SMD ‐0.29, 95% CI ‐0.68 to 0.11, 1 trial), and knee or hip OA (SMD ‐0.31, 95% CI ‐0.41 to ‐0.20, 9 trials, P value for interaction 0.45). Adequately powered trials with 200 or more randomised participants tended to show smaller improvements of function (difference in SMD 0.23, 95% CI ‐0.06 to 0.52, P value for interaction = 0.11) and trials with adequate participant blinding larger benefits of function (difference in SMD ‐0.25, 95% CI ‐0.41 to ‐0.09, P value for interaction = 0.008). Eighteen comparisons from 12 trials contributed to the analysis of a linear association between equivalence dose and treatment benefit for function (<a href="#CD003115-fig-0008">Figure 8</a>). We found no evidence for an association between daily equivalence doses and improvement of function (P value = 0.48). </p> <div class="figure" id="CD003115-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, and 2 active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled." data-id="CD003115-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, and 2 active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled. </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot for effects on functioning of the knee or hip.  Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs" data-id="CD003115-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot for effects on functioning of the knee or hip.<br/> Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Standardised mean differences of function (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Standardised mean differences of function (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> </div> <div class="table" id="CD003115-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Stratified analyses: function</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Variable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of</b> <br/> <b>studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>opioids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> <br/> SMD (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> <br/> I<sup>2</sup> (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.35 to ‐0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Analgesic potency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.42 (‐0.74 to ‐0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.36 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.43 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transdermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.25 (‐0.38 to ‐0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.45 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.23 (‐0.37 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.40 to ‐0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.07 (‐0.20 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 (‐0.34 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.40 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of control intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.38 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.68 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Number of participants randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.23 (‐0.32 to ‐0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.46 (‐0.73 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.25 (‐0.41 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.42 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Use of analgesic co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.40 (‐0.67 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of osteoarthritis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hip only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.68 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.16 (‐0.43 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee and hip</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.41 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>*P value for interaction. N/A: not available.</p> </div> </div> </section> </section> <section id="CD003115-sec-0053"> <h4 class="title">Secondary outcomes</h4> <p>Ten trials reported the occurrence of any adverse event in 2490 out of 3222 participants in experimental groups and 891 of 1676 participants in control groups (<a href="#CD003115-fig-0009">Figure 9</a>). Participants were 49% more likely to experience adverse events in experimental groups compared with placebo (RR 1.49, 95% CI 1.35 to 1.63). The NNTH to cause one additional participant to experience an adverse event, as compared to placebo, was 14 (95% CI 11 to 19) (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). We found high heterogeneity between different studies (I<sup>2</sup> = 71%, P value for heterogeneity &lt; 0.001), but no evidence that RRs differed between different types of opioids (P value for interaction = 0.47) or length of treatment duration (P value = 0.09). Eighteen comparisons in nine trials contributed to the analysis of the association between equivalence dose and log relative risk (<a href="#CD003115-fig-0010">Figure 10</a>). We found little evidence for a relationship (P value = 0.24). </p> <div class="figure" id="CD003115-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis." data-id="CD003115-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Risk ratios of participants experiencing any adverse event between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk ratios of participants experiencing any adverse event between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> </div> <p>Twenty‐one trials with 8128 participants contributed to the meta‐analysis of participants withdrawn or dropped out because of adverse events (<a href="#CD003115-fig-0011">Figure 11</a>). Participants receiving opioid therapy were 3.8 times as likely as participants receiving placebo to be withdrawn or drop‐out due to adverse events (RR 3.76, 95% CI 2.93 to 4.82), with moderate between‐trial heterogeneity (I<sup>2</sup> = 59%, P value for heterogeneity &lt; 0.001). The NNTH to cause one additional drop‐out or withdrawal due to adverse events compared with placebo was 21 (95% CI 15 to 30) (<a href="./full#CD003115-tbl-0001">summary of findings Table for the main comparison</a>). We found the highest pooled RR for oxycodone versus placebo (RR 5.55, 95% CI 3.47 to 8.87, 9 trials) and the lowest pooled RR for morphine versus placebo (RR 2.12, 95% CI 0.87 to 5.15, 2 trials) but CIs were wide and a test for interaction between type of opioids and relative risk of being withdrawn or dropping out because of adverse events negative gave a P value for interaction of 0.41. We found no evidence for an association between treatment duration and risk of withdrawals or drop‐outs due to adverse events (P value for interaction 0.78). Thirty‐two comparisons in 22 trials contributed to the analysis of the association between equivalence dose and log relative risk (<a href="#CD003115-fig-0012">Figure 12</a>). We found little evidence for a relationship (P value = 0.94). </p> <div class="figure" id="CD003115-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop‐outs because of adverse events occurred in either group." data-id="CD003115-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop‐outs because of adverse events occurred in either group. </p> </div> </div> </div> <div class="figure" id="CD003115-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Risk ratios of participants withdrawn or dropped out because of adverse events between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk ratios of participants withdrawn or dropped out because of adverse events between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> </div> <p>Three trials with 681 participants contributed to the analysis of participants experiencing any serious adverse event (<a href="#CD003115-fig-0013">Figure 13</a>). One trial reported one death in the oxycodone group, but no other serious adverse events and was not included in the analysis (<a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>). Of the three trials included, one trial reported that no participant experienced a serious adverse event (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>). Overall data from the remaining two trials indicated that participants receiving opioids tended be more likely to experience a serious adverse event (RR 3.35, 95% CI 0.83 to 13.56). Due to the low number of trials and events, we neither performed an analysis of the association between treatment duration or equivalence dose and log relative risk for this outcome, nor a calculation of NNTH to cause one additional participant to experience a serious adverse event compared with placebo. </p> <div class="figure" id="CD003115-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Forest plot of three trials comparing participants experiencing any serious adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in either group." data-id="CD003115-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of three trials comparing participants experiencing any serious adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in either group. </p> </div> </div> </div> <p>Three trials reported symptoms of opioid dependency (<a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>). Two studies reported 25 of 397 participants with withdrawal symptoms in oral opioids and five of 255 in control groups (<a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>). One study assessed opiate withdrawal symptoms after eight weeks of transdermal fentanyl therapy, using the Short Opiate Withdrawal Scale questionnaire (<a href="./references#CD003115-bbs2-0076" title="GossopM . The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors1990;15(5):487‐90. ">Gossop 1990</a>; <a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>). On average, participants in the opioids groups had a 2.8‐fold increased risk of withdrawal symptoms compared with control groups with a pooled OR of 2.76 (95% CI 2.02 to 3.77) (<a href="#CD003115-fig-0014">Figure 14</a>). The NNTH to cause one additional participant to experience withdrawal symptoms, as compared with control, was 65 (95% CI 42 to 110). </p> <div class="figure" id="CD003115-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios. The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis." data-id="CD003115-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios. The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003115-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003115-sec-0054"></div> <section id="CD003115-sec-0055"> <h3 class="title" id="CD003115-sec-0055">Summary of main results</h3> <p>In this update of our systematic review and meta‐analysis, we found only small benefits of oral or transdermal opioids being more effective compared with placebo in terms of pain relief and improvement of function in people with osteoarthritis. If participants received opioids for more than four weeks, benefits on pain relief were even further reduced. The occurrence of adverse events often caused participants to stop taking the opioids, which is likely to limit the usefulness of opioids in the long term. The potentially higher risk of serious adverse events and substance addiction might further limit their use. The reporting of safety outcomes was incomplete and adverse events were reported in only about half of the trials, and serious adverse events in three trials only. Trials that did report safety outcomes consistently observed a significant increase in the risk of adverse events with opioid use. </p> </section> <section id="CD003115-sec-0056"> <h3 class="title" id="CD003115-sec-0056">Quality of the evidence</h3> <p>Most of the trials were funded by the pharmaceutical industry and we did not have enough data to explore whether the type of funding was associated with the estimated treatment effects. We found larger benefits on pain relief in studies with opioid use for less than four weeks compared with longer treatments, but not dependence of benefits on function or safety outcomes according to treatment duration. Thus, the effectiveness of opioids may drop during chronic use as the analgesic effects of opioids are mediated through opioids receptors, but safety concerns were not affected by this. The relatively low dose of morphine equivalents (median daily dose 67 mg) administered in the included trials might provide an explanation of the small benefits observed as compared with other studies (<a href="./references#CD003115-bbs2-0086" title="MaierC , HildebrandtJ , KlingerR , Henrich‐EberlC , LindenaG , MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non‐tumor associated pain ‐ results of a double‐blind placebo‐controlled trial (MONTAS). Pain2002;97(3):223‐33. ">Maier 2002</a>). Our ability to provide a reliable assessment of dose dependency might have been hampered by the generally low morphine equivalent doses used and the lack of individual participant data. The generally used distinction between weak and strong opioids can be misleading, because the analgesic potency depends also on the dosage. Thus, we calculated morphine equivalence doses to be able to compare different opioids, but found no evidence for dose‐dependent effects. We found little evidence that stronger opioid agents or higher doses of these agents will result in larger treatment effects. However, it is possible that type of opioids interacts with dosage. For instance, higher doses could have larger treatment effects for stronger but not for weaker opioids. The characteristics of the trials included in our review did not allow us to explore such interaction properly. </p> <p>Data on risks of addiction due to opioid therapy is scarce, and currently available trials are not designed to evaluate these issues. There is a clear need for additional randomised trials and observational studies using longer follow‐up times to address the risks of substance dependence associated with different opioids. In this systematic review, only three out of 22 trials reported measures of withdrawal symptoms (<a href="./references#CD003115-bbs2-0012" title="LangfordR , McKennaF , RatcliffeS , VojtassakJ , RicharzU . Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo‐controlled trial. Arthritis and Rheumatism2006;54(6):1829‐37. ">Langford 2006</a>; <a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0009" title="Alpharma . A study of embeda (Kadian NT, ALO‐01) in subjects with pain due to osteoarthritis of the hip or knee. clinicaltrials.gov/show/NCT00420992 (accessed 16 August 2014). JonesJB , WagnerG , MorrisD , StaufferJ . Efficacy of morphine sulfate extended‐release with sequestered naltrexone hydrochloride (ALO‐01) in patients with chronic, moderate to severe pain of osteoarthritis of the hip or knee. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2008 Oct 24‐29; San Francisco. KatzN , HaleM , MorrisD , StaufferJ . Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine2010;122(4):112‐28. KatzN , SetnikB , WebsterL . Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules in older patients. Proceedings of the 29th Annual Scientific Meeting of the American Pain Society; 2010 May 6‐8; Baltimore, MD. ">Katz 2010</a>). Similar to previous systematic reviews of randomised trials on opioids therapy for non‐cancer pain (<a href="./references#CD003115-bbs2-0084" title="KalsoE , EdwardsJE , MooreRA , McQuayHJ . Opioids in chronic non‐cancer pain: systematic review of efficacy and safety. Pain2004;112(3):372‐80. ">Kalso 2004</a>; <a href="./references#CD003115-bbs2-0074" title="FurlanAD , SandovalJA , Mailis‐GagnonA , TunksE . Opioids for chronic noncancer pain: a meta‐analysis of effectiveness and side effects. Canadian Medical Association Journal2006;1(11):1589‐94. ">Furlan 2006</a>), we found that most of the trials included in our review had a treatment duration of several days or a few weeks only. Although some of the newer trials in the update had slightly longer treatment durations (<a href="./references#CD003115-bbs2-0001" title="AfilaloM , EtropolskiMS , KuperwasserB , KellyK , OkamotoA , VanHoveI , et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double‐blind, placebo‐ and active‐controlled phase III study. Clinical Drug Investigation2010;30(8):489‐505. GrünenthalGmbH . A study to evaluate the efficacy and safety of cg5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). KellyK , EtropolskiM , KuperwasserB , OkamotoA , SteupA , vanHoveI , et al. Similar analgesic effect and improved tolerability of tapentadol extended release versus oxycodone controlled release for the management of chronic osteoarthritis knee pain: results from a randomized, double‐blind, phase3 trial. Proceedings of the Annual EULAR Conference; 2009 Jun 10‐13; Copenhagen, Denmark. KellyK , LangeB , EtropolskiM , KuperwasserB , OkamotoA , vanHoveI , et al. Dose stability of tapentadol extended release (ER) for the relief of moderate‐to‐severe chronic osteoarthritic knee pain. Proceedings of the 26th Annual Meeting of the American Academy of Pain Medicine; 2010 Feb 3‐6; San Antonio, TX. LangeB , KuperwasserB , OkamotoA , HäufelT , AshworthJ . Efficacy and safety of tapentadol prolonged release (PR) based on prior experience in patients with chronic osteoarthritis knee pain. Annals of Rheumatic Diseases2010;69:287. LangeR , LangeB , GreeneA , OkamotoA , EtropolskiM , AshworthJ . Short Form‐36 (SF‐36) and EUROQOL‐5 Dimension (EQ‐5D) results from randomized, double‐blind phase 3 studies of tapentadol prolonged release (PR) in patients with moderate to severe chronic nociceptive and neuropathic pain. Osteoarthritis and Cartilage2010;18:S147‐8. ">Afilalo 2010</a>; <a href="./references#CD003115-bbs2-0002" title="BreivikH , LjosaaTM , Stengaard‐PedersenK , PerssonJ , AroH , VillumsenJ , et al. A 6‐months, randomised, placebo‐controlled evaluation of efficacy and tolerability of a low‐dose 7‐day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain2010;1:122‐41. ">Breivik 2010</a>; <a href="./references#CD003115-bbs2-0016" title="Grünenthal . A study to evaluate the efficacy and safety of CG5503 prolonged release (PR) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee. clinicaltrials.gov/show/NCT00486811 (accessed 16 August 2014). ">NCT00486811</a>; <a href="./references#CD003115-bbs2-0018" title="Janssen‐Cilag . Placebo‐controlled trial with OROS hydromorphone hydrochloride to treat patients with moderate to severe pain induced by osteoarthritis of the hip or the knee. clinicaltrials.gov/show/NCT00980798 (accessed 16 August 2014). ">NCT00980798</a>), in none of the trials did participants receive opioids for longer than six months. This is still too short to address the impact of opioid treatment on routine clinical practice in the treatment of a chronic condition such as osteoarthritis. While no evidence of long‐term effects is available from randomised trials, observational studies indicate that long‐term treatment with opioids of chronic conditions such as osteoarthritis may have deleterious effects and do not seem to improve pain relief (<a href="./references#CD003115-bbs2-0073" title="EriksenJ , SjøgrenP , BrueraE , EkholmO , RasmussenNK . Critical issues on opioids in chronic non‐cancer pain: an epidemiological study. Pain2006;125(1‐2):172‐9. ">Eriksen 2006</a>). </p> </section> <section id="CD003115-sec-0057"> <h3 class="title" id="CD003115-sec-0057">Potential biases in the review process</h3> <p>We based our review on a broad literature search. Even though we cannot exclude potential publication bias, it seems rather unlikely that we missed relevant trials (<a href="./references#CD003115-bbs2-0072" title="EggerM , JuniP , BartlettC , HolensteinF , SterneJ . How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment (Winchester, England)2003;7(1):1‐76. ">Egger 2003</a>). Two review authors independently performed selection of trials and data extraction to minimise bias and transcription errors (<a href="./references#CD003115-bbs2-0071" title="EggerM , SmithGD . Principles of and procedures for systematic reviews. In: EggerM , SmithGD , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. London: BMJ Books, 2001:23‐42. ">Egger 2001</a>; <a href="./references#CD003115-bbs2-0078" title="GøtzschePC , HróbjartssonA , MaricK , TendalB . Data extraction errors in meta‐analyses that use standardized mean differences. JAMA2007;298(4):430‐7. ">Gøtzsche 2007</a>). The most recent systematic review on opioids for osteoarthritis (<a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a>), updated in October 2006, considered 18 studies that compared opioids with placebo. We included data from six of these in our meta‐analysis and data from four additional trials (<a href="./references#CD003115-bbs2-0011" title="Kjaersgaard‐AndersenP , NafeiA , SkovO , MadsenF , AndersenHM , KronerK , et al. Codeine plus paracetamol versus paracetamol in longer‐term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double‐blind, multi‐centre study. Pain1990;43(3):309‐18. ">Kjaersgaard‐Andersen 1990</a>; <a href="./references#CD003115-bbs2-0020" title="QuidingH , GrimstadJ , RustenK , StubhaugA , BremnesJ , BreivikH . Ibuprofen plus codeine, ibuprofen, and placebo in a single‐ and multidose cross‐over comparison for coxarthrosis pain. Pain1992;50(3):303‐7. Öhrvik , J . Nonparametric methods in crossover trials. Biometrical Journal1998;7:771‐89. ">Quiding 1992</a>; <a href="./references#CD003115-bbs2-0014" title="MatsumotoAK , BabulN , AhdiehH . Oxymorphone extended‐release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double‐blind, placebo‐ and active‐controlled phase III trial. Pain Medicine2005;6(5):357‐66. ">Matsumoto 2005</a>; <a href="./references#CD003115-bbs2-0010" title="KivitzA , MaC , AhdiehH , GalerBS . A 2‐week, multicenter, randomized, double‐blind, placebo‐controlled, dose‐ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics2006;28(3):352‐64. ">Kivitz 2006</a>). We excluded six trials with tramadol as the experimental intervention and one trial that was likely to have included only a minority of people with osteoarthritis. In our update, we identified 12 additional trials, of which three are unpublished. In conclusion, we are likely to have included all relevant trials in our systematic review. </p> </section> <section id="CD003115-sec-0058"> <h3 class="title" id="CD003115-sec-0058">Agreements and disagreements with other studies or reviews</h3> <p>We excluded tramadol from our review to avoid overlap with another Cochrane review that focused on this specific opioid in osteoarthritis (<a href="./references#CD003115-bbs2-0062" title="CepedaMS , CamargoF , ZeaC , ValenciaL . Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005522.pub2] ">Cepeda 2006</a>). Extracted pain and function outcomes and follow‐up time in the previous systematic review about opioids for osteoarthritis (<a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a>) were similar to our systematic review. Comparing opioids with placebo controls, <a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a> found a large pooled effect for pain intensity (SMD ‐0.79, 95% CI ‐0.98 to ‐0.59) and a moderate pooled effect for function (SMD ‐0.31, 95% CI ‐0.39 to ‐0.24). These effects are consistent with our results for function but are substantially larger for pain reduction. This discrepancy might be due to the exclusion of some trials in our systematic review and to inclusion of newer trials in our update in 2012. <a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a> reported moderate‐to‐large effects of tramadol for pain, between ‐0.36 to ‐0.93 SD units, in several large trials and unrealistically large beneficial effects on pain intensity in an oxycodone trial that was excluded from our review due to the likely very low percentage of participants with knee or hip osteoarthritis (<a href="./references#CD003115-bbs2-0045" title="RothSH , FleischmannRM , BurchFX , DietzF , BockowB , RapoportRJ , et al. Around‐the‐clock, controlled‐release oxycodone therapy for osteoarthritis‐related pain: placebo‐controlled trial and long‐term evaluation. Archives of Internal Medicine2000;160(6):853‐60. ">Roth 2000</a>). These trials often did not report function outcomes and could not, therefore, contribute to the pooled analysis, or they reported considerably smaller effects for function than for pain (<a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a>). In line with other studies, we found that adverse events occurring in participants treated with opioids often caused withdrawals and drop‐outs (<a href="./references#CD003115-bbs2-0084" title="KalsoE , EdwardsJE , MooreRA , McQuayHJ . Opioids in chronic non‐cancer pain: systematic review of efficacy and safety. Pain2004;112(3):372‐80. ">Kalso 2004</a>; <a href="./references#CD003115-bbs2-0074" title="FurlanAD , SandovalJA , Mailis‐GagnonA , TunksE . Opioids for chronic noncancer pain: a meta‐analysis of effectiveness and side effects. Canadian Medical Association Journal2006;1(11):1589‐94. ">Furlan 2006</a>; <a href="./references#CD003115-bbs2-0058" title="AvouacJ , GossecL , DougadosM . Efficacy and safety of opioids for osteoarthritis: a meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2007;15(8):957‐65. ">Avouac 2007</a>; <a href="./references#CD003115-bbs2-0075" title="GehlingM , HermannB , TrybaM . Meta‐analysis of dropout rates in randomized controlled clinical trials: opioid analgesia for osteoarthritis pain. Schmerz2011;25(3):296‐305. ">Gehling 2011</a>). Tramadol may be similar to, or even more effective than, the opioids evaluated in our review in reducing pain and improving function, but safety concerns have to be addressed further (<a href="./references#CD003115-bbs2-0062" title="CepedaMS , CamargoF , ZeaC , ValenciaL . Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005522.pub2] ">Cepeda 2006</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003115-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow chart." data-id="CD003115-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow chart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (‐) a high risk of bias on a specific item." data-id="CD003115-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological characteristics of included trials. (+) indicates low risk of bias, (?) unclear, and (‐) a high risk of bias on a specific item. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no intervention) on knee or hip pain. Values on x‐axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled." data-id="CD003115-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of 22 trials comparing the effects of any type of opioids and control (placebo or no intervention) on knee or hip pain. Values on x‐axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, 3, 2, 2, and 2 active intervention arms in Caldwell 2002, Chindalore 2005, Kivitz 2006, Matsumoto 2005, Hartrick 2009, and Etropolski 2011, respectively, were pooled. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for effects on knee or hip pain.  Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs." data-id="CD003115-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot for effects on knee or hip pain.<br/> Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Standardised mean differences of knee or hip pain (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, and 2 active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled." data-id="CD003115-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of 12 trials comparing the effects of any type of opioids and control (placebo or no intervention) on function. Values on x axis denote standardised mean differences. The plot is stratified according to type of opioids. Matsumoto 2005 contributed with two comparisons and the standard error was inflated and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. Data relating to the 3, 3, and 2 active intervention arms in Caldwell 2002, Kivitz 2006, and Matsumoto 2005, respectively, were pooled. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot for effects on functioning of the knee or hip.  Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs" data-id="CD003115-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot for effects on functioning of the knee or hip.<br/> Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Standardised mean differences of function (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Standardised mean differences of function (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis." data-id="CD003115-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of 10 trials comparing participants experiencing any adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Risk ratios of participants experiencing any adverse event between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Risk ratios of participants experiencing any adverse event between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop‐outs because of adverse events occurred in either group." data-id="CD003115-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of 21 trials comparing participants withdrawn or dropped out because of adverse events between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. Matsumoto 2005, Hartrick 2009, Afilalo 2010, Etropolski 2011, and NCT00486811 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. The risk ratio in one trial could not be estimated because no withdrawals or drop‐outs because of adverse events occurred in either group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Risk ratios of participants withdrawn or dropped out because of adverse events between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals." data-id="CD003115-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Risk ratios of participants withdrawn or dropped out because of adverse events between opioids and control groups (y axis) are plotted against total daily dose of morphine equivalents (x axis). The size of the circles is proportional to the random‐effects weights that were used in the meta‐regression. The dotted line indicates predicted treatment effects (regression line) from univariable meta‐regression by using daily morphine equivalence doses the explanatory variable, and dashed lines represent the 95% confidence intervals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of three trials comparing participants experiencing any serious adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in either group." data-id="CD003115-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Forest plot of three trials comparing participants experiencing any serious adverse event between any opioid and control (placebo or no intervention). Values on x axis denote risks ratios. The plot is stratified according to type of opioid. The risk ratio in one trial could not be estimated because no serious adverse event occurred in either group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios. The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis." data-id="CD003115-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Forest plot of 4 comparisons in three trials comparing participants experiencing withdrawal symptoms between any opioid and control (placebo or no intervention). Values on x axis denote odds ratios. The plot is stratified according to type of opioid. Afilalo 2010 contributed with two comparisons and the number of participants in the placebo group was halved to avoid duplicate counting of participants when including both comparisons in the overall meta‐analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 1 Pain." data-id="CD003115-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 1 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 2 Function." data-id="CD003115-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 2 Function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 3 Number of participants experiencing any adverse event." data-id="CD003115-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 3 Number of participants experiencing any adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 4 Number of participants who withdrew because of adverse events." data-id="CD003115-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 4 Number of participants who withdrew because of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 5 Number of participants experiencing any serious adverse event." data-id="CD003115-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 5 Number of participants experiencing any serious adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003115-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/urn:x-wiley:14651858:media:CD003115:CD003115-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_t/tCD003115-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Opioids versus placebo, Outcome 6 Withdrawal symptoms." data-id="CD003115-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Opioids versus placebo, Outcome 6 Withdrawal symptoms.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/media/CDSR/CD003115/image_n/nCD003115-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003115-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis of the knee or hip </p> <p><b>Settings:</b> various orthopaedic or rheumatology clinics </p> <p><b>Intervention: o</b>ral or transdermal opioids </p> <p><b>Comparison: p</b>lacebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Opioids</b> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intensity</b> </p> <p>Various pain scales.</p> <p>(median follow‐up: 4 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 cm change</b> <br/> on 10‐cm VAS<sup>1</sup> </p> <p>29% improvement</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐2.5 cm change</b> <br/> (Δ ‐0.7 cm, ‐0.9 to ‐0.5)<sup>2</sup> </p> <p><b>41% improvement</b> <br/> (Δ 12%, 9% to 15%)<sup>3</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.28 (‐0.35 to ‐0.20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8275<br/> (22) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 10 (95% CI 8 to 14)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> </p> <p>Various validated function scales.</p> <p>(median follow‐up: 5 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.2 units</b> <br/> on WOMAC (range 0 to 10)<sup>1</sup> </p> <p>21% improvement</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>‐1.8 units on WOMAC</b> <br/> (Δ ‐0.6, ‐0.8 to ‐0.4)<sup>5</sup> </p> <p><b>32% improvement</b> <br/> (Δ 11%, 7% to 14%)<sup>6</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.26 (‐0.35 to ‐0.17)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3553<br/> (12) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 12 (95% CI 10 to 18)<sup>7</sup> </p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any adverse event</b> </p> <p>(median follow‐up: 8 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>224 per 1000 participant‐years<br/> (203 to 245) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.49 (1.35 to 1.63)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4898<br/> (9) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+++O<br/> moderate<sup>9</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 14 (95% CI 11 to 19)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who withdrew because of adverse events</b> </p> <p>(median follow‐up: 6 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000 participant‐years<br/> (50 to 82) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.76 (2.93 to 4.82)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7712<br/> (19) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++++<br/> high </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 21 (95% CI 15 to 30)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing any serious adverse event</b> </p> <p>(median follow‐up: 8 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 participant‐years<sup>8</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000 participant‐years<br/> (3 to 54) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.35 (0.83 to 13.56)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>681<br/> (3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>++OO<br/> low<sup>10</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Little evidence of harmful effect (NNTH not statistically significant)</p> </td> </tr> <tr class="separated"> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal symptoms</b> </p> <p>(median follow‐up: 16 weeks)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 1000 participant‐years<sup>11</sup> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>24 per 100<br/> participant‐years<br/> (18 to 33) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.67 (2.02 to 3.77)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1151<br/> (3) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+++O<br/> moderate<sup>12</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 65 (95% CI 42 to 110)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome; OR: odds ratio; RR: risk ratio; SMD: standardised mean difference; WOMAC: Western Ontario and McMaster Universities Arthritis Index. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>GRADE Working Group grades of evidence<br/> <b>High quality (++++):</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality (+++O):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality (++OO):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality (+OOO):</b> We are very uncertain about the estimate. </p> <p><sup>1</sup> Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, <a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>2</sup> SMDs were back‐transformed onto a 10‐cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72 |SD units in the control group.<br/> <sup>3</sup> Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10‐cm VAS (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>4</sup> Absolute response risks for pain in the control groups were assumed 31% (see methods section).<br/> <sup>5</sup> SMDs were back‐transformed onto a standardised WOMAC disability score ranging from 0 to 10 on the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group.<br/> <sup>6</sup> Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (<a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>7</sup> Absolute response risks for function in the control groups were assumed 26% (see methods section).<br/> <sup>8</sup> Median control risk across placebo groups in large osteoarthritis trials (see methods section, <a href="./references#CD003115-bbs2-0088" title="NüeschE , TrelleS , ReichenbachS , RutjesAWS , BürgiE , SchererM , et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta‐epidemiological study. BMJ2009;339:b3244. ">Nüesch 2009</a>).<br/> <sup>9</sup> Downgraded (1 level) because: 9 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias.<br/> <sup>10</sup> Downgraded (2 levels) because: 3 out of 19 studies reported this outcome, possibly leading to selective outcome reporting bias, the CI of the pooled estimate is wide and crossed no difference.<br/> <sup>11</sup> Median risk across control groups in included trials.<br/> <sup>12</sup> Downgraded (1 level) because 3 out of 22 studies reported this outcome, possible leading to selective outcome reporting bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral or transdermal opioids compared with placebo for osteoarthritis of the knee or hip</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003115-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stratified analyses: pain</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Variable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of</b> <br/> <b>studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>opioids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain intensity</b> <br/> SMD (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> <br/> I<sup>2</sup> (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.35 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Analgesic potency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.51 (‐1.01 to ‐0.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.35 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.41 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transdermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.20 (‐0.29 to ‐0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.44 to ‐0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.35 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.42 to ‐0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.21 (‐0.34 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.14 (‐0.30 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.37 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of control intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.36 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.93 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Number of participants randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.47 (‐0.71 to ‐0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.15 (‐0.22 to ‐0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.40 (‐0.50 to ‐0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Use of analgesic co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.46 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.36 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of osteoarthritis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hip only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.93 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.22 (‐0.41 to ‐0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee and hip</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.38 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*P value for interaction. N/A: not available.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Stratified analyses: pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003115-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Stratified analyses: function</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Variable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of</b> <br/> <b>studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>opioids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N of participants</b> <br/> <b>control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> <br/> SMD (95% CI) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Heterogeneity</b> <br/> I<sup>2</sup> (%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.35 to ‐0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Analgesic potency</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.42 (‐0.74 to ‐0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.26 (‐0.36 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.30 (‐0.43 to ‐0.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transdermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.25 (‐0.38 to ‐0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.45 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.23 (‐0.37 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.32 (‐0.40 to ‐0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inadequate or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.07 (‐0.20 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.13 (‐0.34 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No or unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1953</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.40 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of control intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.28 (‐0.38 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.68 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Number of participants randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.23 (‐0.32 to ‐0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.46 (‐0.73 to ‐0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Duration of treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.25 (‐0.41 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.42 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Use of analgesic co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.40 (‐0.67 to ‐0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.24 (‐0.33 to ‐0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Type of osteoarthritis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hip only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.29 (‐0.68 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.16 (‐0.43 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Knee and hip</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.31 (‐0.41 to ‐0.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*P value for interaction. N/A: not available.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Stratified analyses: function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/full#CD003115-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003115-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.35, ‐0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.30, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Codeine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐1.01, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.42, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.19, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.42, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.47, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Oxymorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.58, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.46, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.35, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.40, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Codeine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.74, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.48, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.38, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.58, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Oxymorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.56, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.45, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants experiencing any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.35, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.09, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Codeine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.94, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.33, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.89, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.47, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Oxymorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.28, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.17, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants who withdrew because of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.76 [2.93, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [1.38, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Codeine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [2.16, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [1.64, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.51 [2.54, 11.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.87, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [3.47, 8.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Oxymorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.32 [2.93, 9.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [1.90, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants experiencing any serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [0.83, 13.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Codeine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.57, 13.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.39 [0.34, 120.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [2.02, 3.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.61, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.12, 75.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.25, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [2.13, 4.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Opioids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003115.pub4/references#CD003115-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003115.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003115-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003115-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003115-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD003115-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD003115-note-0003">தமிழ்</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003115\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003115\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003115\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003115\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003115\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003115.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003115.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003115.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003115.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003115.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715765763"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003115.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715765767"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003115.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8f189e45f55f',t:'MTc0MDcxNTc2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 